Abstract
In studying the evaluation of cimetidine my main interest is: what can we learn from the way the evaluation of cimetidine is being handled that will help us with the next drug to come along of this character? So although I will be talking briefly about some of the results and how economists might use them, I have also in my mind this more fundamental methodological problem in the evaluation of new technologies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Drummond, M.F. (1983). Discussion of Paper by Walan. In: Culyer, A.J., Horisberger, B. (eds) Economic and Medical Evaluation of Health Care Technologies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69439-4_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-69439-4_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-69441-7
Online ISBN: 978-3-642-69439-4
eBook Packages: Springer Book Archive